Recent News

• 03.30.2026 - Acoramidis Significantly Reduces the Risk of All-Cause and Cardiovascular Mortality in Patients with ATTR-CM through Month 54
• 03.30.2026 - BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9
• 03.23.2026 - BridgeBio to Present Long-Term Efficacy and Safety Data from the ATTRibute-CM OLE Trial at the ACC Annual Scientific Sessions
• 03.20.2026 - BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
• 03.11.2026 - BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9
• 03.04.2026 - BridgeBio to Present Additional Data from the Phase 3 FORTIFY Trial at the 2026 MDA Clinical & Scientific Conference

Recent Filings

• 03.30.2026 - EX-99.1 EX-99.1
• 03.30.2026 - 8-K Current report
• 03.26.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 03.20.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.20.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.19.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.16.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.13.2026 - 144 Report of proposed sale of securities
• 03.12.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.10.2026 - 144 Report of proposed sale of securities